Aachen, September 6th 2013. The shareholders of the Grünenthal Group have assigned Dr. Wilhelm Moll, LL.M. (63) member of the supervisory board of the international pharmaceutical company headquartered in Aachen. In a meeting on September 6th, Dr. Moll was additionally elected chairman of the supervisory board. As of October 12th 2013 he will as well take over the responsibility of chairman of the advisory board of the Grünenthal Group. Furthermore, with effect from October 12th 2013 Edouard Croufer (66) has been elected member of the advisory board of Grünenthal Pharma GmbH & Co. KG and Grünenthal GmbH.
Growing in stability
Through the appointment of lawyer Dr. Wilhelm Moll, the Grünenthal shareholders clearly focus on stability and continuity. Dr. Moll has been supporting the strategic development and growth targets of the pharmaceutical company as member of the advisory board since 2011. His general activities as lawyer as well as consultant in the focus areas of labor law, corporate law and commercial law include the support of big (DAX listed) as well as medium-sized and privately-owned companies in a variety of problems.
Edouard Croufer also has extensive experience as member in a variety of supervisory and advisory bodies of privately-owned companies. Between 2005 and 2008 he already acted as member of the advisory board of the Grünenthal Group. Amongst others, he is member of the advisory board of the companies Dalli Werke GmbH & Co. KG and Mäurer & Wirtz GmbH & Co. KG since 2004. Before this, he was General Director of the pharma business of UCB as well partner of the consultancy Arthur D. Little GmbH.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. Building on its unique position in pain treatment, its objective is to become the most patient-centric company and thus to be a leader in therapy innovation.
Grünenthal is one of the last five remaining research-oriented pharmaceutical companies with headquarters in Germany which sustainably invests in research and development. Research and development costs amounted to about 26 percent of revenues in 2012. Grünenthal’s research and development strategy concentrates on selected fields of therapy and state-of-the-art technologies. We are intensely focused on discovering new ways to treat pain better and more effectively, with fewer side-effects than current therapies.
Altogether, the Grünenthal Group has affiliates in 26 countries worldwide. Grünenthal products are sold in more than 155 countries. Today, approx. 4,400 employees are working for the Grünenthal Group worldwide. In 2012, Grünenthal achieved revenues of €973 mn.
More information: www.grunenthal.com.